Peter Sherwin is head of the International Arbitration Group and a Partner in the Litigation Department. He is resident in the New York office, frequently works out of the Paris office, and is a member of the Latin America Practice.
Peter's practice focuses on acting as counsel in complex cross-border commercial disputes, often involving a joint venture, a licensing or distribution relationship, or an acquisition, most of which are resolved in international arbitration and the rest in federal and state courts in the United States. He also has significant sports industry experience. Additionally, Peter regularly serves as an arbitrator in proceedings under the International Arbitration Rules of the International Chamber of Commerce (ICC).
Chambers USA ranks Peter as one of the top International Arbitration lawyers nationwide, reporting that "he is praised for his expert handling of commercial cases across a variety of fields" and is "an extremely talented attorney with a great reputation." Legal 500 Paris reports that he is recommended for "his excellent writing, oratorical skills, and strategic approach.”
Recent matters include representation of:
ABI Bank Ltd, a Caribbean bank, in an ICC arbitration in Miami brought by Andrade Gutierrez, one of the largest Brazilian construction companies, seeking over $35 million in connection with an airport rehabilitation and corresponding long-term bond financing, obtaining a complete victory for the bank
Zilip Pharma, a European biotech company, in an ongoing ICDR arbitration under New York law against Bayer HealthCare concerning its development of Zilip's technology for a longer-acting hemophilia treatment, with claimed damages in excess of $350 million
Votorantim Metais Ltda., a Peruvian mining company, in arbitration and litigation aspects of Latin America transactions, including post-closing indemnity claims in acquisitions
Colgate-Palmolive in a series of ICC arbitrations in Geneva with one of its North African distributors and local manufacturers arising out of the termination and wrapping-up of their business relationship. Obtained a complete victory in all proceedings and was awarded substantial costs and attorneys’ fees
sanofi-aventis in a Swiss Rules arbitration in Zurich with U.S. pharmaceutical company Watson concerning the expiration of distribution and supply rights to a major drug that generates hundreds of millions of dollars in revenue annually, prevailing on nine out of ten claims